Charles River

GettyImages/maxsattana

Charles River to buy MPI Research for $800m

By Flora Southey

Charles River Laboratories International says it is en route to ‘double its size in five years’ with the acquisition of non-clinical CRO MPI Research.

Brains On-Line is a preclinical CRO. (Image: iStock/ktsimage)

Charles River acquisition builds CNS expertise

By Melissa Fassbender

Charles River Laboratories has acquired Brains On-Line in an ongoing effort to deepen its drug discovery capabilities and build out its portfolio through strategic acquisitions.

Charles River splits off and divests CDMO business

Charles River splits off and divests CDMO business

By Dani Bancroft

Charles River Laboratories International Inc. has sold off its CDMO business QS Pharma LLC, saying the small-molecule manufacturing business was “not optimized” within the firm's portfolio.

The acquisition is the latest in a series. (Image: iStock)

Charles River acquires analytical CRO

By Melissa Fassbender

Charles River Laboratories has acquired Blue Stream Laboratories, expanding the company’s biologic and biosimilar development capabilities.

Charles River will continue to broaden its early stage portfolio. (Image: iStock)

Charles River: 2016 to be 'robust year'

By Melissa Fassbender

After reporting a successful FY16, Charles River expects a successful new year driven by customer demand and enhanced strategic partnerships.

Charles River seeing more strategic relationships, CEO says

Charles River seeing more strategic relationships, CEO says

By Zachary Brennan

As Big Pharma and biotech companies continue to outsource more of their work, one of the leaders in the preclinical and discovery space – Charles River Laboratories – is seeing more strategic relationships with both large and small clients, CEO James...

Harlan is making a big push to capture some of the NCI grantees by adopting a new pricing plan

Harlan looks to corner NCI grantees lost by Charles River

By Zachary Brennan

News of the discontinuation of the National Cancer Institute’s (NCI) Animal Production Program has led Charles River Laboratories rival Harlan to vie for the market of grantees that still need animal research models.

New Yelp-like website offers insider perspectives on CROs

New Yelp-like website offers insider perspectives on CROs

By Zachary Brennan

The Life Sciences Strategy Group has launched a new website for biopharma outsourcing professionals, which includes a star-based user ratings program for CROs that’s similar to Yelp’s ratings system of restaurants.

Charles River taking advantage of biotech growth, CEO says

Charles River taking advantage of biotech growth, CEO says

By Zachary Brennan

For the first time ever, Charles River Laboratories is seeing its biotech revenues eclipse its pharma revenues, Jim Foster, chairman, president and CEO of CRL, told participants at the Baird Growth Stock Conference last week.

CRL pushes deeper into an increasingly lucrative Asia

Charles River expands presence in Asia with acquisition

By Zachary Brennan

Early stage drug developer Charles River Laboratories is pushing further into Asia with its purchase of the microbiology subcontractor BRASS Pte Ltd. Terms of the acquisition were not disclosed.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All